DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 194,600 shares, an increase of 28.4% from the November 30th total of 151,500 shares. Based on an average daily volume of 87,500 shares, the short-interest ratio is presently 2.2 days.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DMAC. Geode Capital Management LLC lifted its holdings in shares of DiaMedica Therapeutics by 29.6% during the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after buying an additional 70,070 shares during the period. Blue Trust Inc. purchased a new stake in DiaMedica Therapeutics during the third quarter valued at $185,000. Magnolia Capital Advisors LLC bought a new position in DiaMedica Therapeutics in the second quarter valued at about $87,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in DiaMedica Therapeutics in the third quarter valued at about $40,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Stock Down 1.3 %

Shares of DMAC stock opened at $5.34 on Tuesday. The company has a 50 day moving average price of $4.80 and a 200-day moving average price of $4.04. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.41. The firm has a market capitalization of $228.34 million, a PE ratio of -9.54 and a beta of 1.51.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.